EUCTR2009-017725-19-DE进行中（未招募）不适用
A Phase IIIB multicenter, double-blind, randomized, placebocontrolled study, evaluating the effect of treatment with dalcetrapib 600 mg on Atherosclerotic Disease as measured by I. Coronary Intravascular Ultrasound (IVUS), Quantitative Coronary Angiography II, Carotid B-Mode Ultrasound Intima Medial Thickness (IMT) and total plaque volume in subjects undergoing coronary angiography who have coronary artery disease (CAD).
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Adult patients over the age of 18 years
- •- Angiographic evidence of coronary artery disease
- •- Ultrasound evidence of carotid artery disease
- •- Treated appropriately for dyslipidemia
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Previous exposure to any CETP-inhibitor or -vaccine within the last 3 months before study start
- •- Clinically significant coronary events, transient ischemic attacks or cerebrovascular accident
- •- Severe anemia
- •- Uncontrolled hypertension
- •- Poorly controlled diabetes
研究者
相似试验
已完成
3 期
A Phase IIIB multicentre, randomized, double*blind, double dummy study to compare the efficacy and safety of abatacept administered subcutaneously and intravenously in subjects with rheumatoid arthritis, receiving background methotrexate, and experiencing an inadequate response to methotrexate.Rheumatoid ArthritisNL-OMON31814Bristol-Myers Squibb3
进行中（未招募）
不适用
A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFa Fab' fragment, certolizumab pegol, administered concomitantly with stable-dose DMARDs in patients with moderate to low disease activity rheumatoid arthritis - NDRheumatoid arthritis with moderate to low disease activityMedDRA version: 9.1Level: PTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-000828-40-ITCB S.A. (Casa Madre)170
进行中（未招募）
1 期
A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFa Fab'fragment, certolizumab pegol, administered concomitantly with stable-dose DMARDs in patients with moderate to low disease activity rheumatoid arthritis. - C87076MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2007-000828-40-FRCB Pharma S.A.170
进行中（未招募）
不适用
A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFa Fab'fragment, certolizumab pegol, administered concomitantly with stable-dose DMARDs in patients with moderate to low disease activity rheumatoid arthritis.MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2007-000828-40-PLCB Pharma S.A.200
进行中（未招募）
不适用
A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFa Fab'fragment, certolizumab pegol, administered concomitantly with stable-dose DMARDs in patients with moderate to low disease activity rheumatoid arthritis. - C87076Rheumatoid arthritisEUCTR2007-000828-40-ATCB Pharma S.A.170